Maraviroc: in vitro assessment of drug–drug interaction potential

Por Hyland, Ruth, Dickins, Maurice, Collins, Claire, Jones, Hannah, Jones, Barry
Publicado em 2008

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

Por Ezuruike, Udoamaka, Humphries, Helen, Dickins, Maurice, Neuhoff, Sibylle, Gardner, Iain, Rowland Yeo, Karen
Publicado no Clin Pharmacol Ther (2018)

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

Por Malhotra, Bimal, Dickins, Maurice, Alvey, Christine, Jumadilova, Zhanna, Li, Xiaoxi, Duczynski, Gregory, Gandelman, Kuan
Publicado em 2011

Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction

Por Youdim, Kuresh A, Zayed, Aref, Dickins, Maurice, Phipps, Alex, Griffiths, Michelle, Darekar, Amanda, Hyland, Ruth, Fahmi, Odette, Hurst, Susan, Plowchalk, David R, Cook, Jack, Guo, Feng, Obach, R Scott
Publicado em 2008